Helicobacter pylori Eradication Therapy in Korea.
- Author:
Seung Young KIM
1
;
Sung Woo JUNG
Author Information
- Publication Type:Review
- Keywords: Helicobacter pylori; Drug therapy; Combination
- MeSH: Amoxicillin/therapeutic use; Anti-Bacterial Agents/*therapeutic use; Clarithromycin/therapeutic use; Drug Therapy, Combination; Helicobacter Infections/complications/*drug therapy; *Helicobacter pylori; Humans; Lymphoma, B-Cell, Marginal Zone/complications; Peptic Ulcer/complications; Proton Pump Inhibitors/therapeutic use; Republic of Korea; Stomach Neoplasms/complications
- From:The Korean Journal of Gastroenterology 2011;58(2):67-73
- CountryRepublic of Korea
- Language:Korean
- Abstract: Helicobacter pylori (H. pylori) is known to be associated with many gastrointestinal diseases including peptic ulcer. In Korea, eradication of H. pylori is recommended for peptic ulcer disease, low grade gastric mucosa-associated lymphoid tissue lymphoma, and early gastric cancer. Standard triple therapy using proton pump inhibitor, clarithromycin, and amoxicillin and bismuth-containing quadruple therapy have been the main first-line and second-line therapy for H. pylori in Korea. Although eradication rate of second-line quadruple therapy remains similar to that of the past, the success rate of eradication with triple therapy has decreased with increasing antimicrobial resistance to H. pylori. There is no standard third-line therapy, and some regimens that incorporate levofloxacin, moxifloxacin, and rifabutin can be used. New regimens such as sequential or concomitant therapy are suggested as alternative treatment for H. pylori. We need more well designed randomized controlled studies to choose proper treatment for H. pylori infection.
